Moleculin Biotech (MBRX) Depreciation & Amortization (IS) (2016 - 2025)
Moleculin Biotech's Depreciation & Amortization (IS) history spans 10 years, with the latest figure at $9000.0 for Q4 2025.
- Quarterly results put Depreciation & Amortization (IS) at $9000.0 for Q4 2025, down 70.97% from a year ago — trailing twelve months through Dec 2025 was $90000.0 (down 28.0% YoY), and the annual figure for FY2025 was $90000.0, down 28.57%.
- Depreciation & Amortization (IS) for Q4 2025 was $9000.0 at Moleculin Biotech, down from $21000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (IS) ranged from a high of $44000.0 in Q1 2021 to a low of $9000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (IS) is $32000.0 (2022), against an average of $31800.0.
- The sharpest move saw Depreciation & Amortization (IS) rose 9.38% in 2023, then crashed 70.97% in 2025.
- Year by year, Depreciation & Amortization (IS) stood at $34000.0 in 2021, then dropped by 5.88% to $32000.0 in 2022, then rose by 9.38% to $35000.0 in 2023, then dropped by 11.43% to $31000.0 in 2024, then crashed by 70.97% to $9000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (IS) over the past three periods came in at $9000.0, $21000.0, and $29000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.